Research progress in liver targeted therapy for nonalcoholic fatty liver disease / 临床肝胆病杂志

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD)is the most common progressive liver disease worldwide.Currently,there is no satisfy-ing treatment for NAFLD.Research progress in fatty acid bile acid conjugates (FABACs)and ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE),which are two novel liver targeted drugs with anti-NAFLD effects,is reviewed.FABACs,which reduce liver fat in pa-tients with NAFLD induced by high-fat diet by regulating lipid metabolism,have been proved effective in preventing and treating NAFLD. The safety and efficacy of FABACs in NAFLD patients have been confirmed in a phase II,randomized,double-blind,placebo-controlled trial.UDCA-LPE can not only reduce liver fat in NAFLD patients,but also inhibit mitochondrial damage and apoptosis and promote hepa-tocyte regeneration,with a marked anti-inflammatory effect during the development of NAFLD.Therefore,FABACs and UDCA-LPE hold promise for preventing and treating NAFLD.